- $201.77m
- $136.66m
- $70.14m
- 30
- 25
- 67
- 35
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.33 | ||
| Price to Tang. Book | 2.4 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.88 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -67.58% | ||
| Return on Equity | -65.89% | ||
| Operating Margin | -97.04% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 68.46 | 69.06 | 104.75 | 138.59 | 70.14 | 65.38 | 62.05 | 2.97% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
Directors
- John Nicols PRE (57)
- Ross Taylor CFO (57)
- Jennifer Aaker IND (54)
- Stephen Dilly IND (61)
- Byron Dorgan IND (78)
- Esther Martinborough IND (55)
- Alison Moore IND (54)
- David Smith IND (61)
- Dennis Wolf IND (68)
- Patrick Yang IND (73)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 31st, 2002
- Public Since
- April 22nd, 2010
- No. of Shareholders
- 125
- No. of Employees
- 174
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 70,303,639
- Address
- 200 Penobscot Dr, REDWOOD CITY, 94063-4718
- Web
- https://www.codexis.com/
- Phone
- +1 6504218100
- Contact
- Carrie Mckim
- Auditors
- BDO USA, LLP
Upcoming Events for CDXS
Codexis Inc Annual Shareholders Meeting
Q2 2024 Codexis Inc Earnings Release
Similar to CDXS
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Codexis share price?
As of Today at 19:05 UTC, shares in Codexis are trading at $2.87. This share price information is delayed by 15 minutes.
How has the Codexis share price performed this year?
Shares in Codexis last closed at $2.87 and the price had moved by -35.21% over the past 365 days. In terms of relative price strength the Codexis share price has underperformed the S&P500 Index by -47.68% over the past year.
What are the analyst and broker recommendations for Codexis?
The overall consensus recommendation for Codexis is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Codexis dividend yield?
Codexis does not currently pay a dividend.
Does Codexis pay a dividend?
Codexis does not currently pay a dividend.
When does Codexis next pay dividends?
Codexis does not currently pay a dividend.
How do I buy Codexis shares?
To buy shares in Codexis you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Codexis?
As of the previous close price of $2.87, shares in Codexis had a market capitalisation of $201.77m.
Where are Codexis shares listed?
Here are the trading details for Codexis:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CDXS
What kind of share is Codexis?
Based on an overall assessment of its quality, value and momentum Codexis is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Codexis share price forecast for 2024?
The analyst consensus target price for shares in Codexis is $6.57. That is 128.92% above the last closing price of $2.87.
Analysts covering Codexis currently have a consensus Earnings Per Share (EPS) forecast of -$0.65 for the next financial year.
What is the trend in the Codexis share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Codexis. Over the past six months, its share price has outperformed the S&P500 Index by +23.12%.
As of the last closing price of $2.87, shares in Codexis were trading +11.42% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Codexis PE Ratio?
The Codexis PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.87.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Codexis?
Codexis' management team is headed by:
- John Nicols - PRE
- Ross Taylor - CFO
- Jennifer Aaker - IND
- Stephen Dilly - IND
- Byron Dorgan - IND
- Esther Martinborough - IND
- Alison Moore - IND
- David Smith - IND
- Dennis Wolf - IND
- Patrick Yang - IND